Multicenter, Randomized, Blinded, Placebo Controlled, Cross Over, Single Dose Study to Assess the Effect of Indacaterol (150 μg) Versus Tiotropium (18 μg) on Inspiratory Capacity in Moderate COPD Patients.
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Indacaterol (Primary) ; Tiotropium bromide
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 27 Oct 2011 Primary endpoint 'Inspiratory-capacity' has been met (3065195).
- 27 Oct 2011 Results published in the Respiratory Medicine.
- 30 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.